Most material SEC filings — August 13, 2026

On June 28, 2026, Rocket Lab agreed to merge with Iridium Communications. Iridium shareholders will receive $27.00 cash per share plus 0.2400–0.4000 Rocket Lab shares (depending on Rocket Lab's stock price at closing), valued at approximately $2.86B in stock and $2.86B in cash, plus $1.77B debt payoff and $0.09B equity awards, totaling ~$7.59B. Rocket Lab will finance via a $3.6B bridge facility. Pro forma combined 2H 2026 revenues: $878.7M; net loss: $154.7M.

Chief Executive Officer Huang Jack Jiajia (COE) bought 592K shares (~$11.8M) on the open market (1.6% of holdings). Open-market insider purchase — historically a bullish signal.

PTC Therapeutics won a competitive bankruptcy auction to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111M upfront plus up to $100M in contingent regulatory/commercial milestone payments. BLA submission expected Q4 2026 with potential commercial launch in 2027; the Phase 1/2 STAAR study showed positive renal function improvement (eGFR) and durable clinical benefit over 52 weeks. Transaction expected to close late Q3/early Q4 2026, subject to bankruptcy court approval and customary conditions.

Karyopharm (market cap ~$37M) reported Q2 2026 revenue of $33.4M ($30.8M product, $2.6M other) versus $37.9M YoY; reaffirmed FY2026 guidance of $130–150M total revenue ($115–130M product). Key catalyst: planned August 2026 sNDA submission for selinexor+ruxolitinib in myelofibrosis under Accelerated Approval, supported by Phase 3 SENTRY data. Critical liquidity crisis: cash of $65.4M as of June 30, 2026 covers operations only into September 2026; $15.8M debt payment due September 10, 2026 would breach $10M minimum liquidity covenant, triggering default. Company actively seeking financing/strategic alternatives. Endometrial cancer Phase 3 failed primary endpoint (median PFS 12.75 vs 7.43 months, p=0.0791, one-sided).

X-Energy completed its IPO on April 27, 2026, raising approximately $1.1 billion in net proceeds, and subsequently entered long-term HALEU enrichment service agreements with Centrus Energy Corp. and General Matter to support Xe-100 SMR deployment. The company also announced a $8 million milestone-based investment in SGL Carbon to double European NBG-18 graphite production capacity by 2030. Q2 2026 revenues and grant income reached $54.6 million (154% increase YoY), but operating expenses were $164.6 million, resulting in a net loss of $105.3 million; total liquidity stands at $1.9 billion with no debt.

On August 12, 2026, Pelthos Therapeutics Inc. filed an 8-K disclosing Item 4.02 (Non-Reliance on Previously Issued Financial Statements or Related Audit Report). The filing provides no dollar amounts, specific restatement details, affected periods, or reasons for the restatement in the text provided. Only the filing header and metadata are present.

Chicago Atlantic BDC (LIEN, market cap ~$208M) reported Q2 2026 net investment income of $7.7M ($0.34/share), down from $10.0M ($0.44/share) in Q1 2026—a 23% sequential decline driven by lower investment income ($14.0M vs. $16.7M) despite stable expenses and zero non-accruals. Concurrently, LIEN announced an all-stock merger with affiliated REIT Chicago Atlantic Real Estate Finance (REFI), expected to close Q4 2026; REFI will convert to BDC status, and based on March 31, 2026 NAVs, REFI shareholders will own ~50.5% of the combined entity (pending final NAV-to-NAV exchange ratio calculation). The combined company will have ~$771M in portfolio investments and maintain LIEN's investment strategy focused on cannabis and niche middle-market lending.

Zenas received FDA acceptance of its Biologics License Application for obexelimab (CD19/Fc RIIb inhibitor) for IgG4-RD treatment with PDUFA target date May 27, 2027. Phase 3 INDIGO trial showed 56% reduction in flare risk vs. placebo (HR 0.44, p=0.0005), with 73.2% of patients remaining flare-free. Company has $673.9M cash as of June 30, 2026; projects runway through Q2 2029 assuming FDA approval milestone ($75M from Royalty Pharma) and debt facility draw ($75M from Pharmakon). Net loss Q2 2026 was $111.5M vs. $52.2M prior year; R&D expenses increased $19.9M to $62.9M.

Fermi Inc. signed a binding 15-year lease with TensorWave (first anchor customer) for 222 MW Phase 1 capacity, generating ~$6.5B total contract revenue, with expansion options to ~650 MW. The company appointed Lee McIntire as CEO, established strategic alliance with Hillcore Energy for 2.6 GW additional capacity, signed EPC partnerships with Primoris and TSK, and issued $431.25M of 5.00% convertible senior notes due 2031 (net proceeds $416.8M after $34.5M capped call cost) with conversion price ~$9.52/share and capped call strike at $14.64/share (100% premium, limiting dilution). Three Siemens F-class turbines arrived at Port of Houston; company targeting ~200 MW initial power within 6 months and 1.5 GW over 18-24 months.

Seven surety insurers (Berkshire, Zurich, Markel, Hartford, Euler Hermes, Western Surety, Federal Insurance) entered a Financial Assistance Agreement with Southland Holdings dated August 13, 2026 (effective October 1, 2025). The sureties committed an initial irrevocable $10M+ funding within 60 days, with discretionary additional funding thereafter at 4% annual interest. In return, sureties receive preferred stock equal to 50% of 'Expected Loss' (estimated cost to complete bonded projects), with remaining 50% as unsecured debt subject to forgiveness if projects complete within 20% of budget. Personal guarantors (Renda family, Winn) and 15+ Southland entities pledged substantially all collateral. Preferred shares are perpetual, non-voting, senior to all equity, with liquidation preference and mandatory redemption rights upon restructuring.

Rocket Lab Corporation entered into an Equity Distribution Agreement on August 13, 2026 with Deutsche Bank Securities Inc. and Wells Fargo Securities, LLC as agents, authorizing the issuance and sale of up to $1,944,369,826 in aggregate gross sales price of common stock. The agreement includes both standard at-the-market (ATM) sales and forward stock purchase transactions. Rocket Lab intends to use net proceeds to finance its pending acquisition of Iridium Communications Inc. (announced June 28, 2026 per Merger Agreement) and for general corporate purposes.

Venu Holding (via subsidiaries Notes Live Foundation and Sunset Operations) executed two lease agreements effective May 11, 2026: (1) a ground lease with Sunset Amphitheater LLC for an 8,000-seat amphitheater at Polaris Pointe, Colorado Springs, at $3.222M annual base rent plus 10% escalation every 5 years; (2) an operations lease with AEG Presents Rocky Mountains LLC granting exclusive rights to operate the venue. AEG pays per-ticket base rent (amount redacted) plus revenue sharing—Sunset receives [redacted]% of Venue Profits or bears [redacted]% of Venue Losses. Term commenced August 24, 2024; initial term and renewal options redacted. Landlords (Foundation/Sunset) retain certain event rights and sponsorship control; AEG maintains operational exclusivity within defined geographic radius.

Legence reported Q2 2026 revenues of $1.26 billion (110.7% YoY growth; 60% organic excluding $303.8M Bowers acquisition), with Adjusted EBITDA of $154.6M (114.1% YoY). The company raised FY2026 guidance: revenues to $4.7B–$4.8B (from $4.1B–$4.3B) and Adjusted EBITDA to $565M–$585M (from $470M–$490M). Backlog and awarded contracts reached $5.67B (104.6% YoY increase). However, GAAP net loss was $27.8M (vs. $5.3M loss in Q2 2025), driven by $41.1M in goodwill and long-lived asset impairments, and gross margin compressed to 17.4% from 21.5%.

In May 2026, Cellectar closed a registered direct offering raising ~$31.7M in net proceeds (upfront from ~$35M offering plus up to $105M in milestone-based securities) from institutional investors and management. Cash position grew from $13.2M (Dec 2025) to $34.0M (June 2026). Proceeds fund the Phase 3 confirmatory trial of iopofosine I-131 in Waldenström macroglobulinemia (WM); site activation began, first patient expected early 2027, NDA planned mid-2027 under FDA Accelerated Approval. Phase 2b CLOVER WaM data showed 87.5% ORR and 79.2% MRR in post-BTKi patients (n=24); Phase 1b CLR 125 (triple-negative breast cancer) enrollment initiated.

ADI Global Distribution completed its spin-off from Resideo on August 3, 2026, and began independent NYSE trading on August 4, 2026. Q2 2026 net revenue reached record $1,286 million (up 1% YoY), with net income of $6 million versus a net loss of $283 million in Q2 2025. The company reported gross margin of 22.7% (up 50 bps YoY), Adjusted EBITDA of $86 million (6.7% margin, down 9% YoY), and initiated standalone 2026 guidance: full-year net revenue $4.95-5.0 billion and Adjusted Standalone EBITDA $275-295 million. Post-spin liquidity includes ~$150 million cash and $500 million undrawn revolving credit facility.

On June 17, 2026, Indaptus completed a $12.0M private placement, issuing 20M shares at $0.60/share. Concurrently, the company discontinued enrollment and wound down all Decoy20 clinical studies, eliminating active clinical development programs. As of June 30, 2026, cash/investments totaled $11.6M ($7.6M cash + $4.0M short-term investments). R&D expenses fell 83% YoY to $0.4M (Q2), and net loss improved to $1.8M (Q2) vs. $5.2M prior year. The company is now evaluating strategic alternatives including research collaborations (newly begun in neurological disorders/sleep), potential acquisitions, or investments in other businesses.

Yesway reported Q2 2026 net income of $29.7M (vs. $24.2M prior year) and Adjusted EBITDA of $70.9M, up 35% YoY. The company raised full-year 2026 Adjusted EBITDA guidance from $210-220M to $235-245M. Performance driven by same-store fuel margin expansion to 52.6¢/gallon (up 27.4% YoY), inside merchandise margin expansion to 35.7% (up 50bps), and new store openings. The company operates 450 stores and expects to divest 29 Iowa/Kansas stores by year-end 2026.

Intuitive Machines reported Q2 2026 revenue of $206M (4× YoY), ended with $1.8B backlog (+$1.5B vs. YE 2025), and closed the Goonhilly Earth Station and COMSAT acquisition in August. Company booked $920M in Q2 awards plus $300M in Q3 YTD, signed $600M+ GEO satellite contract, won sixth CLPS lander mission, and expanded national security revenue from 3% to 30%. Cash position: $367M; full-year 2026 guidance: $900M–$1B revenue with positive Adjusted EBITDA. Company remains unprofitable (net loss $115.4M H1 2026) but significantly grew order book and diversified customer base.

MiNK Therapeutics reported initial Day 28 observations from its randomized Phase 2 trial (C-1300-02) of agenT-797 in acute lung injury in Ukraine: treated patients showed improved oxygenation, infection control, ventilator/vasopressor liberation, reduced inflammatory markers, and no major serious adverse events attributed to the drug. The company established a paid named-patient access program in Brazil through Orphan Drug Consulting, enabling per-patient physician requests for agenT-797 under Brazilian regulatory authorization, generating per-patient revenue. Cash position declined to $8.8M (June 30, 2026) from $13.4M (December 31, 2025); Q2 2026 net loss was $3.1M ($0.62/share).

IREN delivered Horizon 1 (50MW direct-to-chip liquid-cooled AI deployment) to Microsoft on August 13, 2026, and achieved NVIDIA Exemplar Cloud status on GB300 NVL72. This is the first of four 50MW units scheduled under Microsoft's $9.7bn five-year contract announced November 2025. IREN targets 480MW capacity by end-2026 and 1.2GW by end-2027.

Global Net Lease completed its acquisition of Modiv Industrial on August 12, 2026, issuing 1.975 newly issued GNL shares for each Modiv common share and $25.00 cash per preferred share. The $535M industrial portfolio addition raises GNL's industrial exposure to ~50% of straight-line rent, extends weighted average lease term from 5.7 to 6.6 years, and is expected to be immediately 4% accretive to AFFO per share on a leverage-neutral basis at 7.6% cash cap rate and 8.7% GAAP cap rate. The partnership agreement was amended to grant GNL's OP a call right on OP units issued to Modiv limited partners, with enhanced redemption amounts (1.25x for two years post-close, 1.50x if called within two years).

AleAnna reported Q2 2026 net income of $3.8 million and Adjusted EBITDA of $4.1 million, the fifth consecutive profitable quarter. The Longanesi field generated ~$9.5 million in conventional segment revenue in Q2 2026 (vs. $4.0 million total revenue in Q2 2025). The company closed with $32.6 million cash and commenced construction at the Gradizza field development project in Q2 2026; year-end 2025 proved reserves increased 47% versus year-end 2024 (per DeGolyer and MacNaughton report).

SOLV Energy reported H1 2026 revenue of $1.628B (up 72% YoY) and completed the July 1, 2026 acquisition of Roberson Waite Electric for $40.9M cash plus up to $9M in contingent payments. The company raised full-year 2026 guidance: revenue to $3.87–$3.97B (from $3.72–$3.82B), Adjusted EBITDA to $485–$505M (from $435–$455M). Gross margins contracted 240 bps YoY to 15.9% due to accounting reclassification and mix shift away from high-margin legacy development projects. Backlog reached $8.9B (+44% YoY); 23+ GW under O&M contract.

Q2 2026 net product revenue for Zelsuvmi (molluscum contagiosum treatment) reached $15.4M, up 45% from Q1's $10.7M. Company raised $30M in January 2026 from Horizon Technology Finance under a $50M senior secured term loan facility; additional $10M is available subject to lender discretion based on achieving $42.3M trailing twelve-month revenues. As of June 30, 2026, cash was $24.2M; 11,925 Zelsuvmi units dispensed in Q2 by 4,571 prescribers (48% QoQ increase); >25,000 patients prescribed since July 2025 launch. Two additional products (Xepi, Xeglyze) planned for Q1 2027 and Q3 2027 launches.

Parabilis completed a $770.5M IPO in June 2026 and ended Q2 2026 with $1.1B in cash (sufficient to fund operations into 2030). Lead program zolucatetide demonstrated 74% ORR in desmoid tumors (25 response-evaluable patients as of Feb 2026) with planned Phase 3 initiation in H1 2027. Separately, Parabilis announced a strategic collaboration with Regeneron on Antibody-Helicon Conjugates, receiving $125M ($50M upfront + $75M equity investment) with potential $2.2B in milestone payments plus tiered royalties.

On August 5, 2026, Lithium Americas entered a securities purchase agreement with Yorkville Advisors to issue up to $175 million in subordinated convertible debentures ($150 million at initial closing, $25 million optional). Concurrently, the company reported Q2 2026 results: $1.8 billion in capitalized Thacker Pass costs (54% of $3.3 billion total budget), 1,600+ workers on-site, mechanical completion targeted for late 2027, and $1.3 billion cash/restricted cash. DOE loan advances total $1.209 billion; ATM program raised $72.7 million through June 30. Company faces $80–100 million in tariff exposure in 2026 and unfavorable cost pressures (inflation, logistics, labor).

Cabaletta Bio raised approximately $91.5M net (cash grew from $133.6M to $225.1M between year-end 2025 and June 30, 2026, per May 2026 registered direct offering). Lead product rese-cel for autoimmune diseases advanced: RESET-Myositis registrational data on track for mid-2027 with first BLA submission planned 2H27; RESET-SSc cohort (~25 patients) anticipated to initiate 4Q26; PC-free approach incorporated into RESET-MG; ElevateBio added as second CDMO alongside Lonza. Q2 2026 R&D expenses $44.4M vs. $37.6M prior year; cash runway extends into mid-2027.

MSG Sports reported FY2026 revenues of $1,153.8M (+11% YoY, +$114.6M) and operating income of $28.9M (+95% YoY, +$14.1M), driven primarily by Knicks' NBA Championship run and higher playoff revenues (+$66.9M in Q4). The company announced a proposed spin-off of its Rangers (NHL) business from the Knicks (NBA) business, with Form 10 confidentially submitted in May 2026 and completion expected by end of October 2026, subject to board approval and various conditions.

Pyxis Oncology completed a private placement on July 2, 2026, receiving $50 million in upfront gross proceeds with up to $64 million additional from warrant exercise. Combined with existing cash of $34.5 million (as of June 30, 2026), this extends runway into Q2 2027. The company reported Q2 2026 net loss of $25.3 million ($0.40 per share on 83.4M shares outstanding); R&D expenses were $16.1M, G&A $9.9M. MICVO monotherapy and combination data updates expected Fall 2026 and Q4 2026.